Merck expects cancer therapy Keytruda to be part of government price setting in 2026
Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government ...
pharmaphorum38m
Can Keytruda finally break into early head and neck cancer?
Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...
Merck expects Keytruda to face HHS price setting in 2026
Merck (MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting ...
Pharm Exec20h
FDA Grants Priority Review to Merck’s Keytruda for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...
The Pharma Letter22h
FDA grants priority review to Merck’s sBLA for Keytruda
The US Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application ...
Cure Today18h
FDA Accepts Priority Review for Pre- and Postsurgical Keytruda in HNSCC
The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...
A little-known Chinese company made a drug that beat the world’s biggest selling medicine
China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend ...
devdiscourse9h
Healthcare Headlines: From West Bank Violence to Overdose Decline
The World Health Organization raises alarms over increased West Bank violence affecting healthcare. In Congo, over 50 die due ...
Pyxis Oncology rises on FDA fast track tag for lead asset
Pyxis Oncology (PYXS) stock rises as the FDA issues fast track designation for its lead asset PYX-201 in head and neck cancer ...
Merck’s application for keytruda in HNSCC granted priority review by FDA
Merck (MRK) announced the FDA has accepted for priority review a new supplemental Biologics License Application seeking approval for keytruda – ...
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
Receiving Fast Track designation for PYX-201 from the FDA marks a significant milestone for Pyxis Oncology, recognizing our potential to address the significant medical need in R/M HNSCC. This ...